Vasopressin, from regulator to disease predictor for diabetes and cardiometabolic risk

Annals of Nutrition and Metabolism

Volumn 68, Issue 2, 2016, Pages 24-28

  Melander, Olle ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Cardiovascular disease; copeptin; Diabetes mellitus; Hydration; Vasopressin

Indexed keywords

COPEPTIN; CORTICOTROPIN; VASOPRESSIN; VASOPRESSIN V1B RECEPTOR; VASOPRESSIN V2 RECEPTOR; GLYCOPEPTIDE; VASOPRESSIN DERIVATIVE; VASOPRESSIN RECEPTOR;

BODY WATER; CARDIOMETABOLIC RISK; CARDIOVASCULAR DISEASE; CONFERENCE PAPER; CUSHING SYNDROME; FLUID INTAKE; GLUCOSE TOLERANCE; HUMAN; HYDROCORTISONE RELEASE; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; PLASMA OSMOLALITY; PREMATURE MORTALITY; PRIORITY JOURNAL; REGULATORY MECHANISM; VASOPRESSIN BLOOD LEVEL; VASOPRESSIN RELEASE; WATER ABSORPTION; ANIMAL; BLOOD; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; DRINKING; ELECTROLYTE BALANCE; NEUROHYPOPHYSIS; OSMOLARITY; PHYSIOLOGY; RISK FACTOR; SECRETION (PROCESS);

ANIMALS; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; DRINKING; GLYCOPEPTIDES; HUMANS; METABOLIC SYNDROME X; OSMOLAR CONCENTRATION; PITUITARY GLAND, POSTERIOR; RECEPTORS, VASOPRESSIN; RISK FACTORS; VASOPRESSINS; WATER-ELECTROLYTE BALANCE;

EID: 84975266391     PISSN: 02506807     EISSN: 14219697     Source Type: Journal    
DOI: 10.1159/000446201     Document Type: Conference Paper

References (40)

1. Laakso M: Hyperglycemia and cardiovascular disease in type 2 diabetes. Diabetes 1999; 48: 937-942.
2. Zimmet P, Alberti KG, Shaw J: Global and societal implications of the diabetes epidemic. Nature 2001; 414: 782-787.
3. Coutinho M, Gerstein HC, Wang Y, Yusuf S: The relationship between glucose and incident cardiovascular events. A metaregression analysis of published data from 20 studies of 95, 783 individuals followed for 12.4 years. Diabetes Care 1999; 22: 233-240.
4. Hauner H: Insulin resistance and the metabolic syndrome - A challenge of the new millennium. Eur J Clin Nutr 2002; 56(suppl 1): S25-S29.
5. Reaven GM: Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988; 37: 1595-1607.
6. Reaven GM: The role of insulin resistance and hyperinsulinemia in coronary heart disease. Metabolism 1992; 41(5 suppl 1):16-19.
7. Patel A, MacMahon S, Chalmers J, Neal B, Billot L, et al; ADVANCE Collaborative Group: Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008; 358: 2560-2572.
8. Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B, et al: Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 2013; 369: 1317-1326.
9. Gerstein HC, Miller ME, Byington RP, Goff DC Jr, Bigger JT, Buse JB, et al: Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008; 358: 2545-2559.
10. Robertson GL: Thirst and vasopressin function in normal and disordered states of water balance. J Lab Clin Med 1983; 101: 351- 371.
11. Russell JA: Vasopressin in septic shock. Crit Care Med 2007; 35(9 suppl):S609-S615.
12. Keller T, Tzikas S, Zeller T, Czyz E, Lillpopp L, Ojeda FM, et al: Copeptin improves early diagnosis of acute myocardial infarction. J Am Coll Cardiol 2010; 55: 2096-2106.
13. Roussel R, Fezeu L, Marre M, Velho G, Fumeron F, Jungers P, et al: Comparison between copeptin and vasopressin in a population from the community and in people with chronic kidney disease. J Clin Endocrinol Metab 2014; 99: 4656-4663.
14. Stoiser B, Mörtl D, Hülsmann M, Berger R, Struck J, Morgenthaler NG, et al: Copeptin, a fragment of the vasopressin precursor, as a novel predictor of outcome in heart failure. Eur J Clin Invest 2006; 36: 771-778.
15. Baumann G, Dingman JF: Distribution, blood transport, and degradation of antidiuretic hormone in man. J Clin Invest 1976; 57: 1109-1116.
16. Struck J, Morgenthaler NG, Bergmann A: Copeptin, a stable peptide derived from the vasopressin precursor, is elevated in serum of sepsis patients. Peptides 2005; 26: 2500-2504.
17. Langdon-Brown W, Seward C: A case of Cushing's syndrome. Br Med J 1935; 2: 253-254.
18. Fujiwara Y, Hiroyama M, Sanbe A, Aoyagi T, Birumachi J, Yamauchi J, et al: Insulin hypersensitivity in mice lacking the V1b vasopressin receptor. J Physiol 2007; 584(pt 1):235-244.
19. Tanoue A, Ito S, Honda K, Oshikawa S, Kitagawa Y, Koshimizu TA, et al: The vasopressin V1b receptor critically regulates hypothalamic- pituitary-adrenal axis activity under both stress and resting conditions. J Clin Invest 2004; 113: 302-309.
20. Tatsuno I, Uchida D, Tanaka T, Koide H, Shigeta A, Ichikawa T, et al: Vasopressin responsiveness of subclinical Cushing's syndrome due to ACTH-independent macronodular adrenocortical hyperplasia. Clin Endocrinol (Oxf) 2004; 60: 192-200.
21. Abu-Basha EA, Yibchok-Anun S, Hsu WH: Glucose dependency of arginine vasopressininduced insulin and glucagon release from the perfused rat pancreas. Metabolism 2002; 51: 1184-1190.
22. Keppens S, de Wulf H: The nature of the hepatic receptors involved in vasopressin-induced glycogenolysis. Biochim Biophys Acta 1979; 588: 63-69.
23. Whitton PD, Rodrigues LM, Hems DA: Stimulation by vasopressin, angiotensin and oxytocin of gluconeogenesis in hepatocyte suspensions. Biochem J 1978; 176: 893-898.
24. Enhörning S, Wang TJ, Nilsson PM, Almgren P, Hedblad B, Berglund G, et al: Plasma copeptin and the risk of diabetes mellitus. Circulation 2010; 121: 2102-2108.
25. Abbasi A, Corpeleijn E, Meijer E, Postmus D, Gansevoort RT, Gans RO, et al: Sex differences in the association between plasma copeptin and incident type 2 diabetes: The prevention of renal and vascular endstage disease ( PREVEND) study. Diabetologia 2012; 55: 1963-1970.
26. Wannamethee SG, Welsh P, Papacosta O, Lennon L, Whincup PH, Sattar N: Copeptin, insulin resistance, and risk of incident diabetes in older men. J Clin Endocrinol Metab 2015; 100: 3332-3339.
27. Cooper-Dehoff R, Cohen JD, Bakris GL, Messerli FH, Erdine S, Hewkin AC, et al: Predictors of development of diabetes mellitus in patients with coronary artery disease taking antihypertensive medications (findings from the International Verapamil SR-Trandolapril Study [INVEST]). Am J Cardiol 2006; 98: 890- 894.
28. Enhörning S, Bankir L, Bouby N, Struck J, Hedblad B, Persson M, et al: Copeptin, a marker of vasopressin, in abdominal obesity, diabetes and microalbuminuria: The prospective Malmö diet and cancer study cardiovascular cohort. Int J Obes (Lond) 2013; 37: 598- 603.
29. Enhörning S, Struck J, Wirfält E, Hedblad B, Morgenthaler NG, Melander O: Plasma copeptin, a unifying factor behind the metabolic syndrome. J Clin Endocrinol Metab 2011; 96:E1065-E1072.
30. Saleem U, Khaleghi M, Morgenthaler NG, Bergmann A, Struck J, Mosley TH Jr, et al: Plasma carboxy-terminal provasopressin (copeptin): A novel marker of insulin resistance and metabolic syndrome. J Clin Endocrinol Metab 2009; 94: 2558-2564.
31. Enhörning S, Hedblad B, Nilsson PM, Engström G, Melander O: Copeptin is an independent predictor of diabetic heart disease and death. Am Heart J 2015; 169: 549-556.e1.
32. Riphagen IJ, Boertien WE, Alkhalaf A, Kleefstra N, Gansevoort RT, Groenier KH, et al: Copeptin, a surrogate marker for arginine vasopressin, is associated with cardiovascular and all-cause mortality in patients with type 2 diabetes (ZODIAC-31). Diabetes Care 2013; 36: 3201-3207.
33. Tasevska I, Enhörning S, Persson M, Nilsson PM, Melander O: Copeptin predicts coronary artery disease cardiovascular and total mortality. Heart 2016; 102: 127-132.
34. Fenske W, Störk S, Blechschmidt A, Maier SG, Morgenthaler NG, Allolio B: Copeptin in the differential diagnosis of hyponatremia. J Clin Endocrinol Metab 2009; 94: 123- 129.
35. Chan J, Knutsen SF, Blix GG, Lee JW, Fraser GE: Water, other fluids, and fatal coronary heart disease: The Adventist health study. Am J Epidemiol 2002; 155: 827-833.
36. Dennis EA, Dengo AL, Comber DL, Flack KD, Savla J, Davy KP, et al: Water consumption increases weight loss during a hypocaloric diet intervention in middle-aged and older adults. Obesity (Silver Spring) 2010; 18: 300- 307.
37. Roussel R, Fezeu L, Bouby N, Balkau B, Lantieri O, Alhenc-Gelas F, et al: Low water intake and risk for new-onset hyperglycemia. Diabetes Care 2011; 34: 2551-2554.
38. Stookey JD, Constant F, Popkin BM, Gardner CD: Drinking water is associated with weight loss in overweight dieting women independent of diet and activity. Obesity (Silver Spring) 2008; 16: 2481-2488.
39. Ferreira-Pêgo C, Guelinckx I, Moreno LA, Kavouras SA, Gandy J, Martinez H, et al: Total fluid intake and its determinants: crosssectional surveys among adults in 13 countries worldwide. Eur J Nutr 2015; 54(suppl 2):35-43.
40. Taveau C, Chollet C, Waeckel L, Desposito D, Bichet DG, Arthus MF, et al: Vasopressin and hydration play a major role in the development of glucose intolerance and hepatic steatosis in obese rats. Diabetologia 2015; 58: 1081-1090.